"The voice for cancer physicians and their patients in Massachusetts."

FDA approves atezolizumab (Tecentriq) for first-line treatment of metastatic NSCLC with high PD-L1 expression

19 May 2020 7:10 AM | Anonymous

The U.S. Food and Drug Administration approved atezolizumab (TECENTRIQ®, Genentech Inc.) for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression (PD-L1 stained ≥ 50% of tumor cells [TC ≥ 50%] or PD-L1 stained tumor-infiltrating immune cells [IC] covering ≥ 10% of the tumor area [IC ≥ 10%]), with no EGFR or ALK genomic tumor aberrations. Read full press release.

© Copyright.  All rights reserved. 

Massachusetts Society of Clinical Oncologists

P.O. Box 549154, Waltham, MA, 02454
Tel: 781.434.7329 | Fax: 781.464.4896 | email: msco@mms.org

Powered by Wild Apricot Membership Software